MedTrace Logo

Role of Positron Emission Tomography in Detecting Primary Tumor in Cases of Metastases of Unknown Origin

NCT06086652 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2023-10-17

No results posted yet for this study

Summary

In most cases of malignancies, the site of origin of the cancer is clear at presentation or identified soon after. However, Metastatic cancer of unknown primary site (MUO) accounts for 3-5% of all malignant neoplasms, and it is defined as metastatic cancer from an unknown primary site, for which no original site can be detected even after performing all possible tests. Most common metastatic sites include the liver, lymph nodes, lungs, and bones.

18F-fluoro-2-deoxyglucose positron emission tomography (FDG-PET) allows whole-body tumor detection and has proven to be useful in patients with metastasis of unknown primary tumor.

Conditions

  • Metastasis of Unknown Origin

Interventions

DIAGNOSTIC_TEST

PET/CT

detection of possible primary tumor

Sponsors & Collaborators

  • Sohag University

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-15
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06086652 on ClinicalTrials.gov